609 related articles for article (PubMed ID: 18379232)
1. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
[TBL] [Abstract][Full Text] [Related]
4. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
Matthews SJ; Lancaster JW
Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic consequences of ventilator-associated pneumonia.
Amin A
Clin Infect Dis; 2009 Aug; 49 Suppl 1():S36-43. PubMed ID: 19619020
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Réa-Neto A; Niederman M; Lobo SM; Schroeder E; Lee M; Kaniga K; Ketter N; Prokocimer P; Friedland I
Curr Med Res Opin; 2008 Jul; 24(7):2113-26. PubMed ID: 18549664
[TBL] [Abstract][Full Text] [Related]
7. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
Merchant S; Gast C; Nathwani D; Lee M; Quintana A; Ketter N; Friedland I; Ingham M
Clin Ther; 2008 Apr; 30(4):717-33. PubMed ID: 18498921
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials.
Jenkins SG; Fisher AC; Peterson JA; Nicholson SC; Kaniga K
Curr Med Res Opin; 2009 Dec; 25(12):3029-36. PubMed ID: 19849650
[TBL] [Abstract][Full Text] [Related]
9. Safety of intravenous infusion of doripenem.
Redman R; File TM
Clin Infect Dis; 2009 Aug; 49 Suppl 1():S28-35. PubMed ID: 19619019
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
Kollef MH; Chastre J; Clavel M; Restrepo MI; Michiels B; Kaniga K; Cirillo I; Kimko H; Redman R
Crit Care; 2012 Nov; 16(6):R218. PubMed ID: 23148736
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
Freire AT; Melnyk V; Kim MJ; Datsenko O; Dzyublik O; Glumcher F; Chuang YC; Maroko RT; Dukart G; Cooper CA; Korth-Bradley JM; Dartois N; Gandjini H;
Diagn Microbiol Infect Dis; 2010 Oct; 68(2):140-51. PubMed ID: 20846586
[TBL] [Abstract][Full Text] [Related]
12. Economic assessment of doripenem versus imipenem in the treatment of ventilator-associated pneumonia.
McGarry LJ; Merchant S; Nathwani D; Pawar V; DeLong K; Thompson D; Akhras K; Ingham M; Weinstein MC
J Med Econ; 2010 Mar; 13(1):142-7. PubMed ID: 20136579
[TBL] [Abstract][Full Text] [Related]
13. Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia.
Joshi M; Metzler M; McCarthy M; Olvey S; Kassira W; Cooper A
Respir Med; 2006 Sep; 100(9):1554-65. PubMed ID: 16487695
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia.
Heyland DK; Dodek P; Muscedere J; Day A; Cook D;
Crit Care Med; 2008 Mar; 36(3):737-44. PubMed ID: 18091545
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia.
Czosnowski QA; Wood GC; Magnotti LJ; Croce MA; Swanson JM; Boucher BA; Fabian TC
Pharmacotherapy; 2009 Sep; 29(9):1054-60. PubMed ID: 19698010
[TBL] [Abstract][Full Text] [Related]
16. Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
Kollef MH; Nathwani D; Merchant S; Gast C; Quintana A; Ketter N
Crit Care; 2010; 14(3):R84. PubMed ID: 20459721
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
Eagye KJ; Banevicius MA; Nicolau DP
Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
[TBL] [Abstract][Full Text] [Related]
18. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?
Eachempati SR; Hydo LJ; Shou J; Barie PS
J Trauma; 2009 May; 66(5):1343-8. PubMed ID: 19430237
[TBL] [Abstract][Full Text] [Related]
19. Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia.
Combes A; Luyt CE; Fagon JY; Wolff M; Trouillet JL; Chastre J
Crit Care Med; 2007 Jan; 35(1):146-54. PubMed ID: 17080004
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intravenous infusion of doripenem.
Restrepo MI
Clin Infect Dis; 2009 Aug; 49 Suppl 1():S17-27. PubMed ID: 19619018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
